title: The contralateral extremity has also benefit from the locally administered bone marrow-derived mononuclear cells and cord blood serum in diabetic ischemic wound healing.
abstract: OBJECTIVE
  Impaired wound healing could be a disaster especially in diabetes and amputation is the major risk. The aim of this study was to evaluate the benefit of BMMCs and CBS on wound healing.
  
  
  METHODS
  Diabetic rats were underwent bilateral limb ischemia and wounding of skin defects on both extremities. The groups were formed as BMMCs (group A), BMMCs and CBS (group B), only CBS (group C), and phosphate buffer solution (group D) that were injected into wounds on right legs.
  
  
  RESULTS
  The complete recovery of right legs was established as a mean of 21.4 ± 1.1 days, 12.9 ± 1.5 days, 30.0 ± 0.0 days and 38.1 ± 1.5 days according to Groups A, B, C, and D (p < 0.05). The recovery of left legs were calculated as a mean of 27.0 ± 0.0 days, 24.0 ± 0.0 days, 35.6 ± 1.1 days and 37.3 ± 1.6 days according to Groups A, B, C and D (p < 0.05). At the end of the recovery, the HE staining showed that vascularity was increased in groups A and B.
  
  
  CONCLUSIONS
  Transplantation of BMMCs and CBS to the ischemic wounds of the diabetic rats accelerate the repair. The recovery was also superior in the same group although the treatment was not applied to the left extremity directly.
authors.affiliation: Department of Cardiovascular Surgery, Turkiye Yuksek Ihtisas Training and Research Hospital, Kizilay sok., Sihhiye, 06100, Ankara, Turkiye, uluss@yahoo.com.
authors.forename: A Tulga
authors.initials: AT
authors.lastname: Ulus
authors.forename: Ferda Alpaslan
authors.initials: FA
authors.lastname: Pınarli
authors.forename: Devrim
authors.initials: D
authors.lastname: Sonmez
authors.forename: Ahmet
authors.initials: A
authors.lastname: Yesilyurt
authors.forename: Tuncay
authors.initials: T
authors.lastname: Delibasi
mesh_terms: D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology; D064987:Cell- and Tissue-Based Therapy; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000628:therapy*; D005312:Fetal Blood / Q000637:transplantation*; D007511:Ischemia / Q000628:therapy*; D007963:Leukocytes, Mononuclear / Q000166:cytology* / Q000637:transplantation*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin; D014945:Wound Healing / Q000187:drug effects
chemical_list: D013311:Streptozocin